Dublin, June 11, 2021 /PRNewswire/– “The North American Preventive Vaccine Market 2020-2026 by Vaccine Type, Disease, Management, Patient, and Country: COVID-19 Impact and Growth Opportunities” Report has been added to ResearchAndMarkets.com provide.
North America The preventive vaccine market is expected to grow 10.42% annually during the forecast period and reach $30.02 billion By 2026, due to the increase in health care expenditures, new development of vaccines, and the increasing demand for preventive vaccines, especially the new COVID-19 vaccine.
The 131-page report “North American Preventive Vaccine Market 2020-2026: COVID-19 Impact and Growth Opportunities by Vaccine Type, Disease, Management, Patient, and Country” focuses on 51 tables and 48 data, based on For the whole North America Through extensive and detailed classification, the preventive vaccine market and all its sub-segments. In-depth analysis and evaluation come from high-quality primary and secondary information sources, and its input comes from industry professionals throughout the value chain. The report is based on 2016-2019 research and provides estimates/forecasts from 2020 to 2026, with 2019 as the base year.
Trends and outlook North America Considering COVID-19, forecast the market with an optimistic, balanced and conservative viewpoint.Balanced (most likely) projection for quantification North America The preventive vaccine market is classified in all aspects from the perspective of vaccine type, disease, management, patient, and country.
According to the type of vaccine, North America The market is segmented into the following sub-markets, each of which contains annual revenue (in millions of US dollars) from 2016 to 2026.
- Live vaccine/attenuated vaccine
- Inactivated vaccine
- Subunit vaccine
- Toxoid vaccine
- Combination vaccine
- Recombinant vector vaccine
- Other vaccines
According to the disease, North America The market is segmented into the following sub-markets, each of which contains annual revenue (in millions of US dollars) from 2016 to 2026.
- Pneumococcal disease vaccine
- Poliovirus vaccine
- Hepatitis vaccine
- Flu vaccine
- Measles, mumps and rubella (MMR) vaccine
- Chickenpox Vaccine
- Human papillomavirus vaccine
- COVID-19 vaccine
- Vaccines for other diseases
According to management, North America The market is segmented into the following sub-markets, each of which contains annual revenue (in millions of US dollars) from 2016 to 2026.
- Intramuscular route
- Subcutaneous route
- Oral route
- Intravenous injection
- Other management approaches
According to the patient, North America The market is segmented into the following sub-markets, each of which contains annual revenue (in millions of US dollars) from 2016 to 2026.
- Pediatric vaccine
- Measles, mumps and rubella (MMR)
- chicken pox
- Haemophilus influenzae type B (HIB)
- other illnesses
- Adult vaccine
- Cervical cancer
- other illnesses
Geographically, a comprehensive survey of the following countries/local markets has been conducted:
For each key country, detailed analysis and data of 2016-2026 annual revenue (millions of dollars) are available. It also includes the breakdown of major country markets by vaccine type, disease, and route of administration in the forecast year.
The report also covers current competition scenarios and predicted trends; and introduces major suppliers, including market leaders and important emerging players.
Specifically, the potential risks associated with investment North America Quantitative and qualitative analysis of the preventive vaccine market through GMD’s risk assessment system. Based on risk analysis and assessment, generate critical success factors (CSF) as a guide to help investors and shareholders identify emerging opportunities, manage and minimize risks, develop appropriate business models, and make smart strategies and decisions.
Key topics covered:
2 Market overview and dynamics
3 North American market by vaccine type
4 North American market segmented by disease
5 North American market by administrative department
6 Segmentation of the North American market by patients
7 North American Market 2020-2026 by Country/Region
8 Competitive landscape
9 Investing in the North American market: risk assessment and management
- Bavaria Nordic A/S
- China National Biotechnology Group Co., Ltd.
- CSL Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Emergency Biological Solutions Company
- Johnson & Johnson
- Moderna Corporation
- Novavax, Inc.
- Takeda Pharmaceutical Co., Ltd.
For more information about this report, please visit https://www.researchandmarkets.com/r/vy6y0c
Research and market
Laura Wood, Senior Manager
For EST office hours, please call +1-917-300-0470
US/Canada toll free number +1-800-526-8630
GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the United States): +353-1-481-1716
Source research and market